
Longeveron Secures $4.4 Million in Funding to Advance Regenerative Medicine Therapies
Longeveron Inc, a leading biotechnology company specializing in regenerative medicine, has successfully raised $4.4 million through a warrant exercise transaction aimed at accelerating its innovative cellular therapies. This funding initiative, overseen by H.C. Wainwright & Co. as the exclusive placement agent, marks a pivotal step in Longeveron’s mission to combat rare and chronic aging-related conditions….